IL124015A0 - Pharmaceutical compositions comprising a protein - Google Patents

Pharmaceutical compositions comprising a protein

Info

Publication number: IL124015A0
Authority: IL; Israel
Prior art keywords: pharmaceutical compositions; protein; cancer; erythropoietin; inhibition
Prior art date: 1998-04-08

Application number

IL12401598A

Other languages

English (en)

Original Assignee

Yeda Res & Dev

Mor Research Applic Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-04-08

Filing date

1998-04-08

Publication date

1999-01-26

1998-04-08 Application filed by Yeda Res & Dev, Mor Research Applic Ltd filed Critical Yeda Res & Dev

1998-04-08 Priority to IL12401598A priority Critical patent/IL124015A0/xx

1999-01-26 Publication of IL124015A0 publication Critical patent/IL124015A0/xx

1999-03-30 Priority to JP2000543153A priority patent/JP4456271B2/ja

1999-03-30 Priority to US09/647,761 priority patent/US6579525B1/en

1999-03-30 Priority to CA2366674A priority patent/CA2366674C/fr

1999-03-30 Priority to AU30527/99A priority patent/AU3052799A/en

1999-03-30 Priority to HK01104635.2A priority patent/HK1033910B/en

1999-03-30 Priority to EP99912039A priority patent/EP1067955B1/fr

1999-03-30 Priority to ES99912039T priority patent/ES2185323T3/es

1999-03-30 Priority to AT99912039T priority patent/ATE222119T1/de

1999-03-30 Priority to PCT/IL1999/000186 priority patent/WO1999052543A2/fr

1999-03-30 Priority to IL13870599A priority patent/IL138705A0/xx

1999-03-30 Priority to DE69902523T priority patent/DE69902523T2/de

2000-09-26 Priority to IL138705A priority patent/IL138705A/en

2003-03-05 Priority to US10/378,970 priority patent/US20030216316A1/en

Links

239000008194 pharmaceutical composition Substances 0.000 title abstract 2
102000004169 proteins and genes Human genes 0.000 title 1
108090000623 proteins and genes Proteins 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 4
201000011510 cancer Diseases 0.000 abstract 3
102000003951 Erythropoietin Human genes 0.000 abstract 2
108090000394 Erythropoietin Proteins 0.000 abstract 2
229940105423 erythropoietin Drugs 0.000 abstract 2
230000005764 inhibitory process Effects 0.000 abstract 2
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 abstract 2
206010027476 Metastases Diseases 0.000 abstract 1
208000034578 Multiple myelomas Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
230000007123 defense Effects 0.000 abstract 1
230000001900 immune effect Effects 0.000 abstract 1
230000009401 metastasis Effects 0.000 abstract 1
230000000638 stimulation Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Organic Chemistry (AREA)
Hematology (AREA)
Oncology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Peptides Or Proteins (AREA)
Magnetic Resonance Imaging Apparatus (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

IL12401598A 1998-04-08 1998-04-08 Pharmaceutical compositions comprising a protein IL124015A0 (en)

Priority Applications (14)

Application Number	Priority Date	Filing Date	Title
IL12401598A IL124015A0 (en)	1998-04-08	1998-04-08	Pharmaceutical compositions comprising a protein
DE69902523T DE69902523T2 (de)	1998-04-08	1999-03-30	Verwendung von erythropoietin zur behandlung von multiple myelom
EP99912039A EP1067955B1 (fr)	1998-04-08	1999-03-30	Utilisation de l'erythropoietine dans le traitement du myelome multiple
US09/647,761 US6579525B1 (en)	1998-04-08	1999-03-30	Pharmaceutical compositions comprising erythropoietin for treatment of cancer
CA2366674A CA2366674C (fr)	1998-04-08	1999-03-30	Compositions pharmaceutiques contenant de l'erythropoietine utilisees dans le traitement du cancer
AU30527/99A AU3052799A (en)	1998-04-08	1999-03-30	Pharmaceutical compositions comprising erythropoietin for treatment of cancer
HK01104635.2A HK1033910B (en)	1998-04-08	1999-03-30	Use of erythropoietin in the treatment of multiple myeloma
JP2000543153A JP4456271B2 (ja)	1998-04-08	1999-03-30	癌の治療のためのエリスロポエチンを含む医薬組成物
ES99912039T ES2185323T3 (es)	1998-04-08	1999-03-30	Utilizacion de eritropoietina en el tratamiento del mieloma multiple.
AT99912039T ATE222119T1 (de)	1998-04-08	1999-03-30	Verwendung von erythropoietin zur behandlung von multiple myelom
PCT/IL1999/000186 WO1999052543A2 (fr)	1998-04-08	1999-03-30	Compositions pharmaceutiques contenant de l'erythropoietine utilisees dans le traitement du cancer
IL13870599A IL138705A0 (en)	1998-04-08	1999-03-30	Pharmaceutical compositions comprising erythropoietin for treatment of cancer
IL138705A IL138705A (en)	1998-04-08	2000-09-26	Use of erythropoietin for treatment of multiple myeloma
US10/378,970 US20030216316A1 (en)	1998-04-08	2003-03-05	Pharmaceutical compositions comprising erythropoietin for treatment of cancer

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IL12401598A IL124015A0 (en)	1998-04-08	1998-04-08	Pharmaceutical compositions comprising a protein

Publications (1)

Publication Number	Publication Date
IL124015A0 true IL124015A0 (en)	1999-01-26

Family

ID=11071408

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
IL12401598A IL124015A0 (en)	1998-04-08	1998-04-08	Pharmaceutical compositions comprising a protein
IL138705A IL138705A (en)	1998-04-08	2000-09-26	Use of erythropoietin for treatment of multiple myeloma

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
IL138705A IL138705A (en)	1998-04-08	2000-09-26	Use of erythropoietin for treatment of multiple myeloma

Country Status (10)

Country	Link
US (2)	US6579525B1 (fr)
EP (1)	EP1067955B1 (fr)
JP (1)	JP4456271B2 (fr)
AT (1)	ATE222119T1 (fr)
AU (1)	AU3052799A (fr)
CA (1)	CA2366674C (fr)
DE (1)	DE69902523T2 (fr)
ES (1)	ES2185323T3 (fr)
IL (2)	IL124015A0 (fr)
WO (1)	WO1999052543A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ522851A (en) *	2000-05-02	2004-11-26	Action Pharma Aps	Treatment of inflammatory diseases associated with neutrophil or eosinophil granulocyt inflitration with EPO optionally with alpha-MSH
DE10219545A1 (de) *	2002-04-26	2003-11-06	Lang Florian	Regulation der Apoptose
DE602005018333D1 (de) *	2004-03-15	2010-01-28	Sunesis Pharmaceuticals Inc	Sns-595 und anwendungsverfahren
US7588745B2 (en) *	2004-04-13	2009-09-15	Si Options, Llc	Silicon-containing products
WO2006006165A2 (fr) *	2004-07-12	2006-01-19	Yeda Research And Development Co. Ltd.	Utilisation de l'erythropoietine permettant d'ameliorer les reponses immunitaires et de traiter les troubles lymphoproliferatifs
US8580814B2 (en) *	2006-04-03	2013-11-12	Sunesis Pharmaceuticals, Inc.	Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4- oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104027333B (zh) *	2006-06-12	2017-05-17	逊尼希思制药公司	治疗癌症的化合物和组合物
NZ621196A (en)	2008-01-22	2015-08-28	Araim Pharmaceuticals Inc	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
NZ602170A (en)	2008-02-08	2014-03-28	Ambrx Inc	Modified leptin polypeptides and their uses
MX2011000859A (es)	2008-07-23	2011-02-24	Ambrx Inc	Polipeptidos g-csf bovinos modificados y sus usos.
PL2342223T3 (pl)	2008-09-26	2017-09-29	Ambrx, Inc.	Zmodyfikowane polipeptydy zwierzęcej erytropoetyny i ich zastosowania
EA200900517A1 (ru) *	2009-04-01	2010-08-30	Общество С Ограниченной Ответственностью "Лэнс-Фарм"	Применение эритропоэтина для лечения миелобластного лейкоза
TWI480288B (zh)	2010-09-23	2015-04-11	Lilly Co Eli	牛顆粒細胞群落刺激因子及其變體之調配物
AU2014290116A1 (en) *	2013-07-17	2016-02-11	Araim Pharmaceuticals, Inc.	Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage
CA2954975C (fr)	2014-06-12	2023-09-05	Andremacon S.R.L.	Utilisation therapeutique de modulateurs fonctionnels inhibant l'erythropoietine
PL230756B1 (pl) *	2015-09-11	2018-12-31	Univ Medyczny W Bialymstoku	Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu
CN106075447B (zh) *	2016-06-24	2018-07-10	中国人民解放军第二军医大学	一种epo受体及其在伴红细胞增多症的肝细胞癌中的应用
WO2025071560A1 (fr) *	2023-09-28	2025-04-03	Rutgers, The State University Of New Jersey	Procédés de diagnostic de malignités à lymphocytes b, de détection de la récidive de malignités à lymphocytes b et de traitement de celles-ci

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU646822B2 (en)	1989-10-13	1994-03-10	Kirin-Amgen Inc.	Erythropoietin isoforms
US6012450A (en) *	1993-01-29	2000-01-11	Aradigm Corporation	Intrapulmonary delivery of hematopoietic drug
US20020052309A1 (en) *	1996-09-11	2002-05-02	Athanasius A. Anagnostou	Method of treating endothelial injury

1998
- 1998-04-08 IL IL12401598A patent/IL124015A0/xx unknown
1999
- 1999-03-30 JP JP2000543153A patent/JP4456271B2/ja not_active Expired - Fee Related
- 1999-03-30 EP EP99912039A patent/EP1067955B1/fr not_active Expired - Lifetime
- 1999-03-30 CA CA2366674A patent/CA2366674C/fr not_active Expired - Fee Related
- 1999-03-30 AT AT99912039T patent/ATE222119T1/de active
- 1999-03-30 ES ES99912039T patent/ES2185323T3/es not_active Expired - Lifetime
- 1999-03-30 WO PCT/IL1999/000186 patent/WO1999052543A2/fr not_active Ceased
- 1999-03-30 US US09/647,761 patent/US6579525B1/en not_active Expired - Lifetime
- 1999-03-30 AU AU30527/99A patent/AU3052799A/en not_active Abandoned
- 1999-03-30 DE DE69902523T patent/DE69902523T2/de not_active Expired - Lifetime
2000
- 2000-09-26 IL IL138705A patent/IL138705A/en not_active IP Right Cessation
2003
- 2003-03-05 US US10/378,970 patent/US20030216316A1/en not_active Abandoned

Also Published As

Publication number	Publication date
DE69902523T2 (de)	2003-04-24
WO1999052543A2 (fr)	1999-10-21
US20030216316A1 (en)	2003-11-20
IL138705A (en)	2007-02-11
ATE222119T1 (de)	2002-08-15
JP2002511419A (ja)	2002-04-16
CA2366674C (fr)	2010-12-21
US6579525B1 (en)	2003-06-17
ES2185323T3 (es)	2003-04-16
HK1033910A1 (en)	2001-10-05
AU3052799A (en)	1999-11-01
DE69902523D1 (de)	2002-09-19
EP1067955B1 (fr)	2002-08-14
WO1999052543A3 (fr)	1999-12-16
JP4456271B2 (ja)	2010-04-28
EP1067955A2 (fr)	2001-01-17
CA2366674A1 (fr)	1999-10-21

Publication	Publication Date	Title
AU3052799A (en)	1999-11-01	Pharmaceutical compositions comprising erythropoietin for treatment of cancer
MY120235A (en)	2005-09-30	Aryloxyarylsulfonylamino hydroxamic acid derivatives
EA199800391A1 (ru)	1999-10-28	Ингибирование роста опухоли антисмысловыми олигонуклеотидами к il-8 и il-8 рецептору
ZA200108258B (en)	2003-03-26	Methods of inducing cancer cell death and tumor regression.
IL143921A (en)	2003-11-23	Compositions for the treatment and prevention of tumor-related disorders, for inhibiting tumor growth and for inhibiting tumor metastasis
MY138140A (en)	2009-04-30	N-aroylphenylalanine derivatives
MY126972A (en)	2006-11-30	4-pyrimidinyl-n-acyl-l-phenylalanines
AP2002002596A0 (en)	2002-09-30	Piperazine and piperidine derivatives.
CA2396865A1 (fr)	2001-08-09	Inhibiteurs de la farnesyl proteine transferase pour le traitement du cancer du sein
DE59912987D1 (de)	2006-02-02	Mittel zur bekämpfung von pflanzenschädlingen
IL134445A0 (en)	2001-04-30	A method of preventing or treating estrogen-dependent diseases and disorders
ATE239509T1 (de)	2003-05-15	Konjugate zur behandlung von prostatakrebs
MY128003A (en)	2007-01-31	4-pyridinyl-n-acyl-l-phenylalanines
AU5173501A (en)	2001-10-08	Polyamine analogues as cytotoxic agents
JP2002511419A5 (fr)	2006-05-11
ZA200003768B (en)	2002-03-27	Methods and compositions for treating diseases and conditions of the eye.
MXPA03003011A (es)	2003-07-14	Metodos para inducir muerte de celulas cancerosas y regresion de tumores.
BG101038A (bg)	1997-10-31	Супресия на растежа на туморни клетки посредствомсиндекан- 1 ектоучастък
DK0581926T3 (fr)	1997-03-17
MXPA05003634A (es)	2005-12-14	Extracto con actividad anti-tumoral y anti-venenosa.
WO2005032595A3 (fr)	2005-12-01	Procedes et compositions d'inhibition de stat5 dans des cellules cancereuses de la prostate
WO2003077874A3 (fr)	2004-08-05	Composes tetrahydroisoquinoleine substitues, procedes de preparation et utilisation de ceux-ci
ATE279918T1 (de)	2004-11-15	Verwendung von aloe-emodin zur behandlung von neuroektodermalen tumoren
WO2000004153A3 (fr)	2000-03-23	Inhibition de la transformation cellulaire par la proteine pea3 humaine
DE59911556D1 (de)	2005-03-10	Arzneimittel zur vermeidung oder behandlung von papillomavirus-spezifischem tumor